This study was conducted on determining the effects of phenytoin on the skeletal system of the fetuses of 13 Wistar Albino rats. The female rats were divided into two groups after the vaginal smear test: the group 1 (control group) included 6 individuals, whereas the group 2 (phenytoin group) comprised 7 animals. A dose of 25 mg/kg/day phenytoin was administered intraperitoneally to pregnant rats on the 8th-10th days of pregnancy and fetuses were obtained by C-section on the 20th day. A number of 82 fetuses were observed by double staining technique. Their lengths and weights were measured, revealing the statistically significant differences between the two groups (p < 0.001). The lengths of the fetuses in the group 2 were determined as to be 14% shorter and the weights 13% lower compared to those in the group 1. Similarly, number of the fetuses obtained in one gestation decreased 9% in the group 2. Ossification of the skull bones in the fetuses of the group 2 was observed eminently to be deteriorated through using dissection microscope and inspection. Costal separation anomaly was observed in the 10 fetuses of the group 2. The separated-laterally located costal components were not attached to the costal arch. Shape malformations in the last two ribs and wide angularity, particularly in the last six ribs, were also determined.
This study has documented that intraperitoneal usage of the pheytoin during pregnancy may cause to different skeletal malformations, even with lower doses, in rat fetuses.
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permanent defects which may lead to death through passing fetal circulation, which is called teratogenesis. 1 Development of embryo is affected by teratogens mostly during the process of organogenesis, which is recognized as the time period from the occurrence of the neural plaque to closure of the plate. It begins usually on the 18th-21st days in human being, prolongs nearly 36 days. Likewise, it starts on the 6th day in rats, going on for 10 days. 1 During this process, teratogenic agents can lead significant congenital anomalies. 2, 3 Nowadays, several antiepileptic drugs (AEDs) are administered to pregnant women who possess the risk of epilepsy periods. There are controversial reports about the effects of these drugs on congenital anomalies. 4, 5 Various researchers have found different malformation incidences on epidemiological studies. The risk of potential birth defects in the babies of epileptic women receiving AEDs is 4-6%. These malformations are related to the nervous system, face, palate, heart, and genital organs. 6 Retrospective and prospective epidemiological studies have reported that even though more than 90% of epileptic women receiving antiepileptic treatment during the pregnancy have given healthy babies through vaginal way. A limited increase on minor anomalies and major malformations in the fetuses who have exposed to antiepileptic drugs such as phenobarbital, diphenylhydantoin, carbamazepine and valproic acid has been suggested. 5, 7, 8 Drugs known as having significant teratogenic effects on human being are diphenylhydantoin (PHT, phenytoin), trimetadion, folic acid antagonists, anticoagulant agents, talidomid, tetracycline, streptomycin, lithium, androgenic hormones, dietil stillbestrol, antineoplastic and antithyroidal drugs, isotretinoin (vitamin A and its analogues) and valproic acid. Phenytoin is an antiepileptic agent used in taking status epilepticus under control and protecting convulsions that occur during/after neurosurgery and severe head trauma. It is also administered in the treatment of mygren, trigeminal neuralgia, and certain psychoses. Yet, it can be applied in the treatment of cardiac arrhythmia, digital intoxication, and myocardial infarction. 9 Phenytoin administration has been documented to increase vertical and slow wave discharges in rats and human beings. Morphologic and behavioral anomalies have been observed in both animals and human beings in the case of phenytoin usage in pregnancy. It also causes fetal hydantoin syndrome (FHS) in human being, which leads to prenatal and postnatal growth-development deterioration, congenital heart disease, and craniofacial defects comprising major malformations and mental retardation. 10, 11 Along with fetal trimetadion syndrome, fetal hydantoin syndrome has been indicated in rats. Likewise, fetal barbiturate syndrome in mice, fetal valproat and fetal karpamazepin syndromes in rats have been documented. No literature report has yet revealed on fetal primidone syndrome in animals including mouse and rat. 10 Phenytoin is a teratogenic agent in rodentia such as mouse and rat. Most common defects observed in rodents treated with phenytoin during pregnancy are cleft lip and/or palate, hydrocephaly, hydronephrosis, and skeletal anomalies such as length retardation in long bones and ectrodactly. 12 Moreover, phenytoin administration has been reported to initiate skeletal defects and high neonatal death rate in rats and cardiac defects and high neonatal death rate in rabbits. Some other studies have also reported embryosid effects of the indicated drugs without observing any malformation at all. 4, 13, 14 This study has been performed on the effects of the phenytoin (diphenylhydantoin sodium salt-PHT) on the skeletal development of the fetuses of Wistar albino rats.
Materials and methods
All protocols were approved by the Animal Care and Use Committee (Ethic Committee) of Erciyes University.
The study was performed in the Hakan Çetinsaya Experimental and Clinical Research Center (DEKAM), Kayseri, Turkey, using a number of 13 four months old adult Wistar albino rats weighing 170-250 g. The female rats were mated with males overnight on a 3 to 1 basis. The female rats were examined for sperm in the vaginal smear next morning, and sperm positive ones were considered as 0.5 day pregnant. The pregnant rats were divided into two groups and each individual was kept in a separate cage. Control group (group 1) had 6 animals while there were 7 rats in experimental group (group 2). All animals were kept under a constant day/night cycle (12 h L/12 h D) for 20 days (pregnancy period) in a climate controlled condition (fresh air and 21 AE 2 8C).
All animals received routinely ad libitum standard rat diet (21% crude protein containing granule pellet). Tap water was supplied ad libitum on a daily basis. On the 20th day of pregnancy, fetuses were isolated by C-section.
Drug treatment
Group-1 (control group): Animals were dosed with an intraperitoneal (IP) dose of 0.3 ml serum physiologic at 09:00 a.m. on the 8th, 9th, and 10th days of the pregnancy.
Group-2 (phenytoin group): Animals were received an intraperitoneal (IP) dose of 25 mg/kg/day phenytoin diluted with serum physiologic at 09:00 a.m. on the 8th, 9th, and 10th days of the pregnancy.
Fetus preparation
On the 20th day of pregnancy, all animals were anaesthetized by ether inhalation, uteruses with the fetuses and placentas were removed by transversal abdominal incision, and dissected carefully. All the fetuses were weighed using a scale with 1/ 100 g sensibility and measured by a compass with 1/10 cm sensibility. They were examined macroscopically and sacrificed with ether.
Fetus staining
A number of 82 fetuses (40 from the group 1 and 42 from the group 2) were chosen for the staining process. They were firstly fixed in 95% ethyl alcohol for 7 days and subsequently put in pure acetone for degreasing for 3 days. Then, skin and internal organs were totally removed to achieve better staining results. The fetuses were later put in the staining solution and stored in the incubator at 38-40 8C for 7 days. They were then rinsed in tap water for 2 h. After that, they were undergone a transparency process to visualize the skeletal system for 14 days and observed by a stereomicroscope (Nikon) for determining possible malformations. Finally, they were transferred into pure glycerin for further usage. Photographs were taken using a Nikon D100 camera (60 mm, micro objective).
Staining solution
Staining solution was prepared by mixing the following sub solutions:
Solution A: Made by melting 300 mg alcian blue in 100 ml 70% ethyl alcohol through constant stirring. Solution B: Made by melting 100 mg alizarin red S in 100 ml 95% ethyl alcohol through constant stirring. 1st step: stained fetuses were put in 1% KOH for 1 day. 2nd step: they were put in 80 cc 1% KOH and 20 cc 20% glycerin for 5 days. 3rd step: they were put in 50 cc 1% KOH and 50 cc 50% glycerin for 5 days. 4th step: they were put in 20 cc 1% KOH and 80 cc 80% glycerin for 5 days.
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Statistical analyses
Statistical analyses were done using SPSS program (Windows version 15.0). The results of lengths and weights of the fetuses were displayed as mean AE SD. The lengths and weights were determined to show normal distribution using Shapiro Wilk normality test (p > 0.05). Lengths and weights of the fetuses between two groups were found to be significantly by different unpaired t-test (p < 0.05).
Results
A number of 40 fetuses were obtained from six mothers in the group 1 and 42 fetuses from seven mothers in the group 2. Number of the fetuses obtained in one gestation decreased 9% in the group 2 as compared to those of the group 1. There were significant differences on the weights and lengths of the fetuses between the two groups (p = 0.0001) ( Table 1) . As compared to those in the group 1, the lengths of the fetuses in the group 2 were 14% shorter and the weights 13% lower.
Bony and cartilage elements of the fetal skeletons were examined using the double staining technique. The bony components were stained red with alizarin red S while the cartilages (epiphysial and joint cartilages, intervertebral discs, and nasal and costal cartilages) stained with alcian blue.
Group 1
Maxilla, mandible, frontal and parietal bones were observed mostly complete ossification and stained red in all the fetuses. However, ossification was not completed in the occipital bone yet. Ossification areas in this bone were located on the dorsal edge, near the parietal bones, and on the ventral edge through the base of the occipital bone. The nasal cartilages were stained blue on the facial area of the skull (Fig. 1A) .
The vertebras, particularly the joint cartilages of the atlas of the vertebral column were markedly stained blue. Edges of the spinous processes, intervertebral discs, and caudal vertebras were fully in cartilage nature and stained blue (Fig. 1B) . The body and arch of all the vertebras, except the caudal ones, were ossified. The two-third of the spinous processes near the arch was also observed to be ossified (Fig. 1A and B) .
The distal one-third of the ribs through the costal knee and the costal cartilages were stained as blue. The cartilage-ossification ratio of the body of the ribs increased as descending caudally (Fig. 1B) .
Joints of the extremities were still cartilage in nature. The cartilage of the scapula and its dorsal margin were also cartilage in nature. Moreover, the glenoid cavity and ventral angle of the scapula stained blue. The scapula also possessed a red-stained main body. Diaphysis ossification was seen in the long bones of the extremities with the presence of the epiphyseal cartilages on the bone edges ( Fig. 2A) .
There were already red-stained areas in the distal phalanx and diaphyses (Fig. 2B ) of the three metacarpal bones, indicating the commencement of the ossification (Fig. 2B) . Rest of the hand skeleton was still in the nature of a cartilage draft.
On the coxal bone, the most developed ossification area was in the diaphysis of the iliac bone (Fig. 2C) . The tarsal bones were in the shape of a cartilage draft (Fig. 2C) . Ossification was determined to begin in the diaphyses of the four, but one, of the metatarsal bones ( Fig. 2C and D) . The proximal and medial phalanges were yet completely cartilaginous in nature (Fig. 2D ). There were red stained areas determined in the distal phalanx (Fig. 2D) . It was also noted that all the three phalanges of the toe were completely cartilaginous in nature (Fig. 2D) .
Group 2
There were three various developmental stages in the ossification process of the skull bones in the group 2 (Fig. 3) , classified as ''none'', ''slight'' and ''fine'' ( Table 2) . Of the 42 fetuses, there were no ossification signs yet in the nasal bones of the 28, the frontal bones of the 10, the parietal bones of the 26, the occipital bones of the four, and the mandible of the one fetuses (Fig. 3A ). There were also some fetuses whose cartilage drafts were not even formed yet (Fig. 3B) . Ossification was ''fine'' in the nasal bones of the 12, the frontal bones of the 16, the parietal bones of the 14, the occipital bones of the 11, the maxillae of the 30, and the mandibles of the 31 [ [ ( ) T D $ F I G ] Fig. 3 . View of the skeleton craniale in phenytoin group of rats. mx: maxilla, mb: mandibula, n: nasal bone, f: frontal bone, p: parietal bone o: occipital bone.
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fetuses (Fig. 3C) . Pinpoint ossification areas were also observed in the fetuses (Fig. 3D) . Joint cartilages in the vertebral column were stained as blue. Distal one-third of the spinous processes, intervertebral discs and caudal vertebrae were cartilaginous in nature (Fig. 4A) . Ossifications at various levels were documented in all the components of the vertebral column, but caudal ones, of the 17 fetuses in the group 2. Intensity of the ossification gradually decreased from the 7th thoracic vertebra through caudal direction, and the caudal vertebras were fully cartilaginous in nature yet. There were also no ossifications determined in the lumbar and sacral vertebras in the 25 fetuses.
Costal separation anomaly were observed in the 10 fetuses of the group 2 (Fig. 4) . The locations and sides of the anomalies were displayed in detail on Table 3 . The separated and laterally located costal components were not attached to the costal arch (Fig. 4A-C) . Costal ossification was determined to be deteriorated in the fetuses of the group 2, particularly in those which possessed this anomaly (Fig. 4D) .
No ossification was observed in the humeral diaphysis of three fetuses (Fig. 5B) , ossification was present in a narrow area in that of three fetuses (Fig. 5B) , and ''fine'' ossification was seen in that of 36 fetuses (Fig. 5A and B) . Likewise, no ossification was determined in the radius of seven fetuses and in the ulna of five fetuses, but pinpoint ossification areas were documented in the diaphysis of these bones in nine fetuses (Fig. 5A) . ''Fine'' ossification was displayed in the radius of 26 fetuses and in the ulna of 28 fetuses (Fig. 5A and B) . Of the metacarpal bones, ossification was eminent in the 2nd, 3rd, and 4th ones in 13 fetuses. Deficiency was also seen in the cartilage drafts of the metacarpal bones and phalanges in the four fetuses. No ossification was determined in any of the cartilage drafts of the phalanges in the group 2 ( Fig. 5A and B) .
''Slight'' ossifications were observed in the bones of the hind limbs in the fetuses of the group 2; yet, structural deformations and curvatures were seen in the cartilage drafts of these bones. Ossification was ''fine'' in the coxal bones of 22 (Fig. 5D) , ''slight'' in 11 (Fig. 5C ), and ''none'' in 9 ( Fig. 5C ) fetuses of the group 2.
''Fine'' ossification was seen in the body of the femur in 17 (Fig. 5C ), ''slight'' ossification in 9 (Fig. 5D) , and ''none'' ossification in 16 (Fig. 5C ) fetuses of this group. Thus, tibia in 6 fetuses and fibula in 8 fetuses were completely cartilaginous in nature yet (Fig. 5C ). Nasal bone  28  2  12  Frontal bone  10  16  16  Parietal bone  26  2  14  Occipital bone  4  27  11  Maxilla  -12  30  Mandible  1  10  31 ''None'': no ossification was observed, ''slight'': pinpoint or very small ossification areas were seen, ''fine'': diaphyseal ossification was complete or very wide ossification areas were determined.
[ ( ) T D $ F I G ] Fig. 4 . View of the skeleton thoracis in phenytoin group of rats. Black arrow heads: costal angulation, black arrows: costal separation. Tarsal cartilage drafts were prominent in all the fetuses in the group 2, but no ossification was observed (Fig. 5C and D) . While ''none'' ossification was seen in the metatarsal bone drafts of 28 fetuses (Fig. 5C) , ''slight'' ossification was determined in 14 fetuses (Fig. 5D) . None of the phalanges of the hind limbs was ossified, but the presence of the cartilage drafts was eminent. Thus, deformations and deteriorations were determined in the cartilage development of the phalanges (Fig. 5C ).
Discussion
Animal experiment is the first scientific preference to learn whether a substance does have a teratogenic effect or not. It is the most-acceptable way for drug producers to determine potential teratogenic effect of any given drug on human health. In relation to that, this study documented the teratogenic effect of the phenytoin on the skeletal development of the rat fetuses. It has been indicated that occurrence and intensity of this effect depend on the dose and administration way of the drug, and the gestation stage.
On previous experimental studies, phenytoin has been administered to mice and rats orally (through diet or gastric probe), 4, [19] [20] [21] [22] subcutaneously 14, 23 and intraperitonealy. 12,14,19, 24 Harbison has indicated that its oral and subcutan administrations have less effect, as compared to intraperitoneal usage. 19 Similarly, this study has also documented that intraperitoneal usage of phenytoin is much more effective. Doses of the phenytoin administration to mice have been applied in various studies as 40-250 mg/kg orally, 4, 19, 20, 21 50 mg/kg subcutaneously, 23 and 6.25-150 mg/kg intraperitoneally. 19, 24 Similarly, it has been administered in rats as 100 mg/kg orally, 22 150-200 mg/kg subcutaneously, 14 and 100-180 mg/kg intraperitoneally. 12, 14 In our study, an intraperitoneal dose of 25 mg/kg phenytoin was applied to the rats. Such a low dose administration, which is yet only one-fourth of the lowest dose, 100 mg/kg, seen in the literature, has not been used so far in experimental studies on rats.
Time of phenytoin administration varies in the literature. Hansen has given oral phenytoin to mice within a period from 3 weeks before conception throughout pregnancy and has injected a single dose on the 10th day of the pregnancy. 20 In the same way, Sullivan has given this substance to mice with a gastric probe on the 12th-16th days of the pregnancy 4 and Eluma has used a gastric probe to give it to three mouse groups on the 8th-10th, 11th-13th and 14th-16th, and 8th-16th days of the pregnancy. 21 Beck 24 has done three injections on the 11th-13th days of the pregnancy while Gibson and Becker 23 has applied subcutaneous phenytoin on the 7th-9th and 11th-13th days of the pregnancy. Schardein has also injected phenytoin to mice on the 11th-13th days of the pregnancy. 25 Harbison has given phenytoin to pregnant mice within a period from 8th to 14th days of the gestation. 19 Harbison has applied a single daily dose to a mouse group of 6-8 individuals from 7th to 15th days of the gestation. 14 He has also administered phenytoin on the 7th-10th, 10th-15th, and 13th-15th days of the gestation by forming different animal groups. It has been suggested from the results of this study that the later phenytoin is applied the more eminent anomalies are observed. Ata et al. 22 have given daily phenytoin to mice from 7th to 19th days of the gestation, and Abela has applied a single dose on the 11th day of the pregnancy. 12, 22 In our study, a daily single dose of phenytoin has been administered to the rats on the 8th-10th days of the pregnancy.
Gibson has shown that the number of litter decreases in the case of diphenylhydantoin administration to Swiss-Webster mice on the 7th-9th days of the pregnancy. 23 Likewise, Abela and Ata have reported that prenatal treatment of the phenytoin leads to a decrease in the number of litter and fetal weight in rats. 12, 22 The results of Gibson have suggested that a subcutaneous dose of 50 mg/ kg/day diphenylhydantoin on the 7th-9th days of the gestation increases body weight and CRL in the A/J fetuses. However, these values decrease in the case of giving the same dose through same way on the 11th-13th days of the pregnancy. Eluma, Hansen, and Harbison have also documented that the fetal weights of the phenytoin-administered mice decline. 19, 20 In our study, there were 14% decrease in CRL, 13% in fetal weight, and 9% in litter number of the phenytoin given rats, as compared to those of the control group. Phenytoin has been indicated to cause maxillary hypoplasia in rats. 12 In our study, ossification deteriorations have been determined in the 12 fetuses of the phenytoin given group, the group 2. Studies have reported ectrodactily and syndactily cases in the phenytoin applied mice. 4, 19, 20 However, no literature report has so far indicated similar digit anomalies in rats. In our results, while no syndactily was observed, there were obvious deteriorations in either all or some of the cartilage drafts of the phalanges, and metacarpal and metatarsal bones, suggesting the presence of the ectrodactily.
Harbison has indicated that phenytoin leads to a worsening in the ossification process of the long bones in the mouse fetus. 19 Similarly, we obtained similar results in rats, along with costal anomalies. Sullivan and Eluma have reported exencephaly in mouse fetuses after giving 120 mg/kg and 125 mg/kg phenytoin, respectively, through gastric probe. 4, 21 We also observed malformations in the ossification of the frontal bone in the rat fetuses, suggesting the presence of this anomaly. Phenytoin has been reported to cause phalanx and digit hypoplasia and orofacial malformations in babies. Prenatal and postnatal growth deterioration, extremity defects (hypoplasia in distal phalanges and digits), major malformations, and mental retardation have also been documented. 5, 8, 10 Tavlı, Hanson, and Yerby have observed fetal hydantoin syndrome (FHS) in human being, which is characterized as short nose, flattened nose bridge, hipoplasia in digits, curve-like or cleft lips, and cardiac septum defects. [26] [27] [28] In our study, we have not focused primarily on such possible anomalies in soft tissues, since it was not in the scope of this study. Indeed, the results on the skeletal system have been documented, which are similar to those indicated in the literature reports on human beings. Phenytoin has long been known amply to cause congenital malformations in pregnancy. 29 It has also been documented to be a teratogenic agent in both mice and rats. 14, 19, 25, [29] [30] [31] [32] In these studies, the following common malformations and defects have been observed in the fetuses of pregnant rodents treated with phenytoin; cleft lip and/or palate, hydrocephaly, hydronephrose, and skeleton anomalies including growth retardation in long bones and ectrodactly. 4 In our study, no cleft lip neither cleft palate was seen in the fetuses of the phenytoin treated rats. On the other hand, growth retardation and lack of digits were determined in the fore-and hind-limbs. Consequently, we have documented that phenytoin is a teratogenic substance, even with the lower doses, on the bone development of rats. It should not be used in pregnancy unless otherwise required. Even if doing so, its teratogenic effect should be considered in relation with the dose, administration way, and timing.
